Home › PAREXEL Expands Model-Based Drug Development Offering
 

Keywords :   


PAREXEL Expands Model-Based Drug Development Offering

2015-07-10 05:41:00| drugdiscoveryonline News Articles

PAREXEL International Corporation, a leading global biopharmaceutical services provider, recently announced expanded services and capabilities in model-based drug development (MBDD) through their Quantitative Clinical Development (QCD) group.

Tags: development drug offering expands

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.10GEW promotes Billy Adams to VP of operations
08.10Constantia Flexibles earns Letter of Compatibility from RecyClass
08.10Saalt Adds Teen Line
08.10Wise acquires continuous and unit set business forms assets of Victor Printing
08.10Hurricane Milton Public Advisory Number 14A
08.10Summary for Hurricane Milton (AT4/AL142024)
08.10Atlantic Tropical Weather Outlook
08.10Eastern North Pacific Tropical Weather Outlook
More »